Table 2.
2013–2015 | 2017–2019 | 2020–2022 | P1 value | P2 value | |
---|---|---|---|---|---|
EV-A71.N | |||||
Age group, month n (%) | < 0.001 | – | |||
0–11 | 99 (5.78) | 12 (8.00) | – | ||
12–23 | 434 (25.34) | 27 (18.00) | – | ||
24–47 | 893 (52.13) | 58 (38.67) | – | ||
> 48 | 287 (16.75) | 53 (35.33) | – | ||
In outpatient, n (%) | |||||
Inpatient | 332 (19.38) | 9 (6.00) | – | ||
Outpatient | 1381 (80.62) | 141 (94.00) | – | ||
CV-A16.N | 1759 | 891 | 152 | ||
Age group,month n (%) | < 0.001 | 0.225 | |||
0–11 | 106 (6.03) | 56 (6.29) | 7 (4.61) | ||
12–23 | 457 (25.98) | 193 (21.66) | 31 (20.39) | ||
24–47 | 942 (53.55) | 369 (41.41) | 47 (30.92) | ||
≥ 48 | 254 (14.44) | 273 (3064) | 67 (44.08) | ||
In outpatient, n(%) | 0.016 | 0.285 | |||
Inpatient | 84 (4.78) | 25 (2.81) | 2 (1.32) | ||
Outpatient | 1675 (95.22) | 866 (97.19) | 150 (98.68) | ||
Other enterovirus 1, N | 9127 | 7175 | 3196 | ||
Age group, month n (%) | < 0.001 | < 0.001 | |||
0–11 | 1130 (12.38) | 1001 (13.95) | 365 (11.42) | ||
12–23 | 3438 (37.67) | 2648 (36.91) | |||
24–47 | 3823 (41.89) | 2678 (37.32) | |||
> 48 | 736 (8.06) | 848 (11.82) | |||
In outpatient, n(%) | < 0.001 | 0.016 | |||
Inpatient | 645 (7.07) | 356 (4.96) | 124 (3.88) | ||
Outpatient | 8482 (92.93) | 6819 (95.04) | 3072 (96.12) |
Other enterovirus 1: No-EV-A71 and No-CY-A16 enterovirus; P1 value: the data in 2017–2019 compared with 2013–2015; P2 value: the data in 2020–2022 compared with 2017–2019; The chi-square test was used for all analysis in the Table 2